Niagen Bioscience Secures New Patent for NAD+ Delivery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy NAGE?
Source: Newsfilter
- Patent Expansion: Niagen Bioscience has secured U.S. Patent No. 12,558,367, covering the methods of use for nicotinamide riboside (NR) in intravenous and injectable formulations, with expected protection until 2044, thereby enhancing its competitive edge in the rapidly growing NAD+ market.
- Product Innovation: The next-generation intravenous formulation of pharmaceutical-grade Niagen supports faster NAD+ level elevation without the severe side effects associated with traditional NAD+ IV, significantly improving patient comfort and reinforcing the commercial relevance of this newly issued patent.
- Market Coverage: Niagen IV products are now available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., and with the protection of the new patent, the company can expand additional commercial pathways and partnerships, enhancing market penetration.
- Intellectual Property Advantage: Niagen Bioscience owns over 100 patents, ensuring its leadership in the NAD+ precursor space, and the acquisition of this new patent further solidifies its intellectual property moat, supporting future commercial expansion and innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
12.00
Averages
16.33
High
23.00
Current: 5.050
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen Bioscience Secures New Patent for IV and Injectable NR Formulations
- Patent Expansion: Niagen Bioscience has secured U.S. Patent No. 12,558,367, covering the methods of use for nicotinamide riboside (NR) and its derivatives in intravenous and injectable formulations, with expected protection lasting until 2044, thereby enhancing the company's competitive edge in the healthy aging market.
- Product Innovation: The next-generation intravenous formulation of Niagen supports faster infusion rates and elevates NAD+ levels without the severe side effects associated with traditional NAD+ IV, reinforcing the commercial relevance of this newly issued patent.
- Market Coverage: Niagen IV products are now available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., allowing the company to better meet the growing demand for healthy aging solutions and drive sales growth.
- Intellectual Property Protection: The new patent provides significant protection for NR in IV and injectable formats, covering multiple administration routes and combination uses, further expanding the company's commercial pathways and partnership opportunities while enhancing the durability of the Niagen product portfolio.
See More
Niagen Bioscience Secures New Patent for NAD+ Delivery
- Patent Expansion: Niagen Bioscience has secured U.S. Patent No. 12,558,367, covering the methods of use for nicotinamide riboside (NR) in intravenous and injectable formulations, with expected protection until 2044, thereby enhancing its competitive edge in the rapidly growing NAD+ market.
- Product Innovation: The next-generation intravenous formulation of pharmaceutical-grade Niagen supports faster NAD+ level elevation without the severe side effects associated with traditional NAD+ IV, significantly improving patient comfort and reinforcing the commercial relevance of this newly issued patent.
- Market Coverage: Niagen IV products are now available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., and with the protection of the new patent, the company can expand additional commercial pathways and partnerships, enhancing market penetration.
- Intellectual Property Advantage: Niagen Bioscience owns over 100 patents, ensuring its leadership in the NAD+ precursor space, and the acquisition of this new patent further solidifies its intellectual property moat, supporting future commercial expansion and innovation.
See More
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
- Conference Sponsorship: Niagen Bioscience is the headline sponsor for the inaugural “NAD for Health: Opportunities & Challenges” scientific meeting scheduled for March 23-25, 2026, in Copenhagen, aimed at fostering interdisciplinary dialogue to advance NAD+ science and healthy aging research.
- Scientific Themes: The conference will focus on NAD metabolism and its implications for human health, bringing together thought leaders from renowned institutions to facilitate exchanges between basic, translational, and clinical research, identifying key knowledge gaps to accelerate clinical translation.
- Global Livestream: The event will feature thematic sessions and a panel discussion, which will be livestreamed globally to broaden access to the latest advances in NAD biology and therapeutic potential, ensuring wider participation and information dissemination.
- Registration Details: Space is limited and registration is required; interested individuals must contact Niagen Bioscience's Events Manager by February 15, 2026, to confirm attendance, ensuring the meeting's efficiency and professionalism.
See More
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
- Event Timing and Location: Niagen Bioscience is the headlining sponsor of the inaugural NAD for Health conference, taking place from March 23-25, 2026, at the Royal Danish Academy of Sciences in Copenhagen, aimed at fostering evidence-based dialogue in NAD+ science and accelerating clinical translation, expected to attract top experts globally.
- Scientific Themes and Objectives: The conference will focus on NAD metabolism and its implications for human health, covering topics such as rare diseases, healthspan extension, and neurodegenerative diseases, with the goal of identifying knowledge gaps and accelerating clinical translation through interdisciplinary dialogue.
- Participants and Program Structure: The meeting will bring together researchers, clinicians, and industry partners from renowned institutions, featuring thematic sessions, a panel discussion, and a dedicated poster session for early-career researchers, facilitating the sharing of new insights.
- Registration and Participation Limitations: Due to limited space, registration is required, and attendance is subject to confirmation, highlighting the high demand for the conference and its significance in the NAD research field, further enhancing Niagen Bioscience's industry influence.
See More
Niagen Bioscience to Host Q4 and FY 2025 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on March 4, 2026, at 4:30 p.m. ET to discuss its Q4 and FY 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Call Details: Participants are required to dial in at least 10 minutes prior to the call, with toll-free dial-in number +1 800 715 9871 and conference ID 8584242, ensuring smooth participation for investors.
- Replay Information: The call will be available for replay from 7:30 p.m. ET on March 4 to 11:59 p.m. ET on March 11, with a replay dial-in number of +1 800 770 2030 and replay ID 8584242, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Niagen Bioscience is a global leader in NAD+ science and healthy aging research, dedicated to advancing healthspan through innovative NAD+ boosting solutions, highlighting its significant position and influence in the industry.
See More
Niagen Bioscience to Host Q4 2025 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on March 4, 2026, at 4:30 p.m. ET to discuss its Q4 and fiscal year 2025 financial results, with the press release issued after market close to ensure timely access to critical information for investors.
- Investor Participation Details: Management advises participants to dial in at least 10 minutes early, with the toll-free number +1 800 715 9871 and conference ID 8584242 provided to facilitate smooth participation in the discussion.
- Replay Information: The call will be broadcast live and available for replay on the company's investor relations website, with replay access from 7:30 p.m. ET on March 4 to 11:59 p.m. ET on March 11, allowing investors who cannot attend live to catch up on the discussion.
- Company Overview: Niagen Bioscience is a global leader in NAD+ science and healthy aging research, committed to advancing healthspan through innovative NAD+ boosting solutions, backed by a robust patent portfolio and collaborations with leading research institutions to ensure scientific validity and efficacy of its products.
See More
Niagen Bioscience Secures New Patent for IV and Injectable NR Formulations
- Patent Expansion: Niagen Bioscience has secured U.S. Patent No. 12,558,367, covering the methods of use for nicotinamide riboside (NR) and its derivatives in intravenous and injectable formulations, with expected protection lasting until 2044, thereby enhancing the company's competitive edge in the healthy aging market.
- Product Innovation: The next-generation intravenous formulation of Niagen supports faster infusion rates and elevates NAD+ levels without the severe side effects associated with traditional NAD+ IV, reinforcing the commercial relevance of this newly issued patent.
- Market Coverage: Niagen IV products are now available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., allowing the company to better meet the growing demand for healthy aging solutions and drive sales growth.
- Intellectual Property Protection: The new patent provides significant protection for NR in IV and injectable formats, covering multiple administration routes and combination uses, further expanding the company's commercial pathways and partnership opportunities while enhancing the durability of the Niagen product portfolio.
See More
Niagen Bioscience Secures New Patent for NAD+ Delivery
- Patent Expansion: Niagen Bioscience has secured U.S. Patent No. 12,558,367, covering the methods of use for nicotinamide riboside (NR) in intravenous and injectable formulations, with expected protection until 2044, thereby enhancing its competitive edge in the rapidly growing NAD+ market.
- Product Innovation: The next-generation intravenous formulation of pharmaceutical-grade Niagen supports faster NAD+ level elevation without the severe side effects associated with traditional NAD+ IV, significantly improving patient comfort and reinforcing the commercial relevance of this newly issued patent.
- Market Coverage: Niagen IV products are now available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., and with the protection of the new patent, the company can expand additional commercial pathways and partnerships, enhancing market penetration.
- Intellectual Property Advantage: Niagen Bioscience owns over 100 patents, ensuring its leadership in the NAD+ precursor space, and the acquisition of this new patent further solidifies its intellectual property moat, supporting future commercial expansion and innovation.
See More
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
- Conference Sponsorship: Niagen Bioscience is the headline sponsor for the inaugural “NAD for Health: Opportunities & Challenges” scientific meeting scheduled for March 23-25, 2026, in Copenhagen, aimed at fostering interdisciplinary dialogue to advance NAD+ science and healthy aging research.
- Scientific Themes: The conference will focus on NAD metabolism and its implications for human health, bringing together thought leaders from renowned institutions to facilitate exchanges between basic, translational, and clinical research, identifying key knowledge gaps to accelerate clinical translation.
- Global Livestream: The event will feature thematic sessions and a panel discussion, which will be livestreamed globally to broaden access to the latest advances in NAD biology and therapeutic potential, ensuring wider participation and information dissemination.
- Registration Details: Space is limited and registration is required; interested individuals must contact Niagen Bioscience's Events Manager by February 15, 2026, to confirm attendance, ensuring the meeting's efficiency and professionalism.
See More
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
- Event Timing and Location: Niagen Bioscience is the headlining sponsor of the inaugural NAD for Health conference, taking place from March 23-25, 2026, at the Royal Danish Academy of Sciences in Copenhagen, aimed at fostering evidence-based dialogue in NAD+ science and accelerating clinical translation, expected to attract top experts globally.
- Scientific Themes and Objectives: The conference will focus on NAD metabolism and its implications for human health, covering topics such as rare diseases, healthspan extension, and neurodegenerative diseases, with the goal of identifying knowledge gaps and accelerating clinical translation through interdisciplinary dialogue.
- Participants and Program Structure: The meeting will bring together researchers, clinicians, and industry partners from renowned institutions, featuring thematic sessions, a panel discussion, and a dedicated poster session for early-career researchers, facilitating the sharing of new insights.
- Registration and Participation Limitations: Due to limited space, registration is required, and attendance is subject to confirmation, highlighting the high demand for the conference and its significance in the NAD research field, further enhancing Niagen Bioscience's industry influence.
See More
Niagen Bioscience to Host Q4 and FY 2025 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on March 4, 2026, at 4:30 p.m. ET to discuss its Q4 and FY 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Call Details: Participants are required to dial in at least 10 minutes prior to the call, with toll-free dial-in number +1 800 715 9871 and conference ID 8584242, ensuring smooth participation for investors.
- Replay Information: The call will be available for replay from 7:30 p.m. ET on March 4 to 11:59 p.m. ET on March 11, with a replay dial-in number of +1 800 770 2030 and replay ID 8584242, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Niagen Bioscience is a global leader in NAD+ science and healthy aging research, dedicated to advancing healthspan through innovative NAD+ boosting solutions, highlighting its significant position and influence in the industry.
See More
Niagen Bioscience to Host Q4 2025 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on March 4, 2026, at 4:30 p.m. ET to discuss its Q4 and fiscal year 2025 financial results, with the press release issued after market close to ensure timely access to critical information for investors.
- Investor Participation Details: Management advises participants to dial in at least 10 minutes early, with the toll-free number +1 800 715 9871 and conference ID 8584242 provided to facilitate smooth participation in the discussion.
- Replay Information: The call will be broadcast live and available for replay on the company's investor relations website, with replay access from 7:30 p.m. ET on March 4 to 11:59 p.m. ET on March 11, allowing investors who cannot attend live to catch up on the discussion.
- Company Overview: Niagen Bioscience is a global leader in NAD+ science and healthy aging research, committed to advancing healthspan through innovative NAD+ boosting solutions, backed by a robust patent portfolio and collaborations with leading research institutions to ensure scientific validity and efficacy of its products.
See More
